Personalis (NASDAQ:PSNL) Lowered to “Strong Sell” Rating by Zacks Research

Zacks Research downgraded shares of Personalis (NASDAQ:PSNL) from a hold rating to a strong sell rating in a research report released on Tuesday morning,Zacks.com reports.

A number of other research firms also recently commented on PSNL. Morgan Stanley boosted their price target on Personalis from $9.00 to $13.00 and gave the company an “equal weight” rating in a research note on Thursday, July 9th. TD Cowen restated a “buy” rating on shares of Personalis in a research note on Wednesday, July 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Personalis in a research note on Friday, July 17th. Needham & Company LLC cut Personalis from a “buy” rating to a “hold” rating in a report on Monday. Finally, Lake Street Capital downgraded Personalis from a “buy” rating to a “hold” rating and set a $16.25 price objective for the company. in a research report on Monday. Four analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $14.25.

Personalis Price Performance

PSNL opened at $12.47 on Tuesday. The company has a market capitalization of $1.31 billion, a PE ratio of -12.23 and a beta of 2.24. The business has a fifty day simple moving average of $11.36 and a 200 day simple moving average of $9.01. Personalis has a 1 year low of $3.84 and a 1 year high of $16.39.

Personalis (NASDAQ:PSNL) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06). Personalis had a negative return on equity of 43.52% and a negative net margin of 148.11%.The business had revenue of $15.47 million for the quarter, compared to the consensus estimate of $14.48 million. Equities analysts anticipate that Personalis will post -1.07 earnings per share for the current fiscal year.

Insider Transactions at Personalis

In other Personalis news, CEO Christopher M. Hall sold 100,000 shares of the stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $13.15, for a total value of $1,315,000.00. Following the completion of the transaction, the chief executive officer directly owned 235,986 shares in the company, valued at approximately $3,103,215.90. This trade represents a 29.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Aaron Tachibana sold 51,251 shares of Personalis stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $13.18, for a total value of $675,488.18. Following the sale, the chief financial officer directly owned 198,833 shares in the company, valued at $2,620,618.94. The trade was a 20.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 435,032 shares of company stock valued at $5,599,929. Insiders own 4.20% of the company’s stock.

Hedge Funds Weigh In On Personalis

Large investors have recently modified their holdings of the business. Caitong International Asset Management Co. Ltd grew its stake in shares of Personalis by 76.1% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock worth $27,000 after purchasing an additional 1,479 shares during the last quarter. International Assets Investment Management LLC acquired a new stake in Personalis during the 4th quarter worth about $31,000. Legal & General Group Plc bought a new position in shares of Personalis in the 2nd quarter worth about $30,000. BNP Paribas Financial Markets lifted its stake in shares of Personalis by 406.4% in the 2nd quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock valued at $42,000 after purchasing an additional 5,177 shares during the period. Finally, AQR Capital Management LLC bought a new stake in shares of Personalis during the 4th quarter valued at about $82,000. Institutional investors own 61.91% of the company’s stock.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.